Literature DB >> 35580060

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.

Aleksandr Ianevski1,2, Anil K Giri1,3, Tero Aittokallio1,2,4,5.   

Abstract

SynergyFinder (https://synergyfinder.fimm.fi) is a free web-application for interactive analysis and visualization of multi-drug combination response data. Since its first release in 2017, SynergyFinder has become a popular tool for multi-dose combination data analytics, partly because the development of its functionality and graphical interface has been driven by a diverse user community, including both chemical biologists and computational scientists. Here, we describe the latest upgrade of this community-effort, SynergyFinder release 3.0, introducing a number of novel features that support interactive multi-sample analysis of combination synergy, a novel consensus synergy score that combines multiple synergy scoring models, and an improved outlier detection functionality that eliminates false positive results, along with many other post-analysis options such as weighting of synergy by drug concentrations and distinguishing between different modes of synergy (potency and efficacy). Based on user requests, several additional improvements were also implemented, including new data visualizations and export options for multi-drug combinations. With these improvements, SynergyFinder 3.0 supports robust identification of consistent combinatorial synergies for multi-drug combinatorial discovery and clinical translation.
© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2022        PMID: 35580060      PMCID: PMC9252834          DOI: 10.1093/nar/gkac382

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   19.160


  32 in total

Review 1.  Rational Cancer Treatment Combinations: An Urgent Clinical Need.

Authors:  Julia Boshuizen; Daniel S Peeper
Journal:  Mol Cell       Date:  2020-06-18       Impact factor: 17.970

2.  Quantifying Drug Combination Synergy along Potency and Efficacy Axes.

Authors:  Christian T Meyer; David J Wooten; B Bishal Paudel; Joshua Bauer; Keisha N Hardeman; David Westover; Christine M Lovly; Leonard A Harris; Darren R Tyson; Vito Quaranta
Journal:  Cell Syst       Date:  2019-02-20       Impact factor: 10.304

3.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18

4.  Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.

Authors:  Geraint Davies; Martin Boeree; Dave Hermann; Michael Hoelscher
Journal:  PLoS Med       Date:  2019-07-09       Impact factor: 11.069

5.  SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.

Authors:  Aleksandr Ianevski; Sanna Timonen; Alexander Kononov; Tero Aittokallio; Anil K Giri
Journal:  PLoS Comput Biol       Date:  2020-02-03       Impact factor: 4.475

6.  A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates.

Authors:  Dennis Wang; James Hensman; Ginte Kutkaite; Tzen S Toh; Ana Galhoz; Jonathan R Dry; Julio Saez-Rodriguez; Mathew J Garnett; Michael P Menden; Frank Dondelinger
Journal:  Elife       Date:  2020-12-04       Impact factor: 8.140

Review 7.  Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.

Authors:  Judith M White; Joshua T Schiffer; Rachel A Bender Ignacio; Shuang Xu; Denis Kainov; Aleksandr Ianevski; Tero Aittokallio; Matthew Frieman; Gene G Olinger; Stephen J Polyak
Journal:  mBio       Date:  2021-12-21       Impact factor: 7.867

Review 8.  Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.

Authors:  Paul Thoueille; Eva Choong; Matthias Cavassini; Thierry Buclin; Laurent A Decosterd
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.790

9.  SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Authors:  Aleksandr Ianevski; Liye He; Tero Aittokallio; Jing Tang
Journal:  Bioinformatics       Date:  2017-08-01       Impact factor: 6.937

10.  Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.

Authors:  Elias Laurin Meyer; Peter Mesenbrink; Cornelia Dunger-Baldauf; Ekkehard Glimm; Yuhan Li; Franz König
Journal:  Pharm Stat       Date:  2022-01-31       Impact factor: 1.234

View more
  3 in total

1.  GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL.

Authors:  Paolo Sportoletti; Emanuela Rosati; Filomena De Falco; Chiara Rompietti; Daniele Sorcini; Angela Esposito; Annarita Scialdone; Stefano Baldoni; Beatrice Del Papa; Francesco Maria Adamo; Estevão Carlos Silva Barcelos; Erica Dorillo; Arianna Stella; Mauro Di Ianni; Isabella Screpanti
Journal:  Cell Death Dis       Date:  2022-09-01       Impact factor: 9.685

2.  Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma.

Authors:  Alexander Schulz; Jennifer Raetz; Paula C Karitzky; Lisa Dinter; Julia K Tietze; Isabell Kolbe; Theresa Käubler; Bertold Renner; Stefan Beissert; Friedegund Meier; Dana Westphal
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

3.  Novel Synergistic Anti-Enteroviral Drug Combinations.

Authors:  Aleksandr Ianevski; Eva Zusinaite; Tanel Tenson; Valentyn Oksenych; Wei Wang; Jan Egil Afset; Magnar Bjørås; Denis E Kainov
Journal:  Viruses       Date:  2022-08-25       Impact factor: 5.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.